Literature DB >> 20085955

Composite end points in randomized trials: there is no free lunch.

George Tomlinson1, Allan S Detsky.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20085955     DOI： 10.1001/jama.2009.2017

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  31 in total

1.  ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

Authors:  Ralph M Meyer; Mary K Gospodarowicz; Joseph M Connors; Robert G Pearcey; Woodrow A Wells; Jane N Winter; Sandra J Horning; A Rashid Dar; Chaim Shustik; Douglas A Stewart; Michael Crump; Marina S Djurfeldt; Bingshu E Chen; Lois E Shepherd
Journal:  N Engl J Med       Date:  2011-12-11       Impact factor: 91.245

2.  Rapid response teams improve outcomes: no.

Authors:  Ritesh Maharaj; Henry T Stelfox
Journal:  Intensive Care Med       Date:  2016-02-05       Impact factor: 17.440

3.  Endpoint selection and relative (versus absolute) risk reporting in published medication trials.

Authors:  Michael Hochman; Danny McCormick
Journal:  J Gen Intern Med       Date:  2011-08-13       Impact factor: 5.128

4.  An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.

Authors:  Roland A Matsouaka; Aneesh B Singhal; Rebecca A Betensky
Journal:  Stat Methods Med Res       Date:  2016-12-29       Impact factor: 3.021

5.  Potential new gene therapy option with sitimagene ceradenovec for newly diagnosed patients with glioblastoma multiforme.

Authors:  Timothy T Cavanagh; Lisa M Holle
Journal:  Cancer Biol Ther       Date:  2013-12-18       Impact factor: 4.742

6.  Primary Endpoints in Pediatric Efficacy Trials Submitted to the US FDA.

Authors:  Dionna J Green; Janelle M Burnham; Paul Schuette; Xiaomei I Liu; Brian M Maas; Lynne Yao; Susan K McCune; Joseph Chen; John N van den Anker; Gilbert J Burckart
Journal:  J Clin Pharmacol       Date:  2018-04-17       Impact factor: 3.126

7.  Statistical Approaches to Composite Endpoints.

Authors:  William S Weintraub
Journal:  JACC Cardiovasc Interv       Date:  2016-11-28       Impact factor: 11.195

Review 8.  Development of a composite endpoint for randomized controlled trials in pancreaticoduodenectomy.

Authors:  Marielle M E Coolsen; Stefan H E M Clermonts; Ronald M van Dam; Bjorn Winkens; Massimo Malagó; Giuseppe K Fusai; Cornelis H C Dejong; Steven W M Olde Damink
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

9.  Outcomes of the Shunt Tube Exposure Prevention Study: A Randomized Clinical Trial.

Authors:  Hosam Sheha; Celso Tello; Lama A Al-Aswad; Mohamed S Sayed; Richard K Lee
Journal:  Ophthalmol Glaucoma       Date:  2019-08-16

10.  Rating the preferences for potential harms of treatments for cardiovascular disease: a survey of community-dwelling adults.

Authors:  Guangxiang Zhang; Puja B Parikh; Soraya Zabihi; David L Brown
Journal:  Med Decis Making       Date:  2013-02-13       Impact factor: 2.583
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.